ARMP - Armata Pharmaceuticals Inc
NYSE * Health Care * Biotechnology
$10.60
$-0.36 (-3.28%)
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
ARMP Key Statistics
Market Cap
$385.91M
P/B Ratio
2.11
EPS
$-1.61
Revenue Growth
-0.6%
Employees
60
How ARMP Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#6
of 6
Size Rank
#6
of 6
Armata Pharmaceuticals Inc Company Information
- Headquarters
- California; U.S.A
- Website
- www.armatapharma.com
- Sector
- Health Care
- Industry
- Biotechnology